Endocrinology Scientific Center
Moscow, Russia
NCT Number: NCT02574195
The main aim of the present study is to evaluate the prevalence of individual microvascular and macrovascular complications among diabetes mellitus patients and to determine the percentage of diabetes mellitus patients achieved HbA1c<7,0%.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Moscow, Russia
Rationale for this Study Primary Existing routine health statistics underestimates the rate of morbidity due to diabetes complications. To provide more realistic estimation of morbidity, repeated epidemiological studies are essential in assessment of tendencies in diabetes medical care at the country level. They allow to reveal issues, which, being resolved, can contribute to the improvement of diabetes medical care effectiveness. Guidelines developed with this study data may save healthcare budgets and prevent financial losses due to diabetes-related morbidity and disability.
Objectives of the Study • Primary objective: To determine the prevalence of individual microvascular and macrovascular complications among patients with diabetes mellitus type 1 and type 2
Study design The hired medical team (9 specialists) is going to perform the technical study-related tasks in Moscow Region.
Target population includes approximately 147,000 diabetes mellitus patients included in Regional Diabetes Mellitus Register, from which patients will be selected via random sampling (600 patients).
A special rented medical bus will accommodate the study personnel at the place and all the local study-related activities.
After obtaining a written Informed Consent Form by local endocrinologist the each study subject will have one study visit, when he or she should appear fasting and the following data will be collected, tests and examination performed:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The subject population for this study must meet the following criteria:
The prescription of the medicinal product is clearly separated from the decision to include the subject in the study.
Exclusion criteria
Time frame: 30 days
macrovascular complications, i.e. with history of
e) microvascular complications, i.e.
Time frame: 30 days
Time frame: 30 days
Endocrinology Research Centre, Moscow
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsNCT01407640
Allergy, Autoimmune Diseases
Paris, France
View Trial DetailsNCT03908125
Autoimmune Diseases, Diabetes Mellitus
Newport Beach, California, United States
View Trial DetailsNCT04869761
Autoimmune Diseases, Chronic Disease
Jacksonville, Florida, United States
View Trial Details